直近一年間の累計
アクセス数 : ?
ダウンロード数 : ?
ID 116746
著者
板東, 浩 Tokushima University|Japan Low Carbohydrate Diet Promotion Association KAKEN研究者をさがす
キーワード
semaglutide
Rybelsus
Peptide InnOvatioN for Early diabEtes tReatment (PIONEER)
absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate
Novo Nordisk
資料タイプ
学術雑誌論文
抄録
Glucagon-Like Peptide 1 receptor agonist (GLP-1RA) have been recently effective for diabetes. Among them, subcutaneous injection and oral form of semaglutide (Rybelsus) are in focus, in which the latter has been examined in the Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) studies. Rybelsus could been invented for absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, due to 30-year process of innovation by Novo Nordisk. It shows clinical effects for diabetes and obesity. For PIONEER 9 and 10 trials, efficacy and safety were shown for 3, 7 or 14 mg of Rybelsus equivalent to subcutaneous liraglutide and subcutaneous dulaglutide for 52 weeks.
掲載誌名
International Journal of Endocrinology and Diabetes
ISSN
26943875
出版者
Pubtexto Publishers
5
1
開始ページ
130
発行日
2022-01-28
権利情報
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
医学系